Service is in preparation Official β release coming soon. Some features are still being adjusted.

Investical Earnings & investing calendar Earnings & investing calendar
/
TTOWA PHARMACEUTICAL CO.,LTD. logo
4553TSE Prime

TOWA PHARMACEUTICAL CO.,LTD.

東和薬品 Yahoo Finance

Recent & upcoming events

Aug 6
Earnings 2:00
Q1 earnings announcement (scheduled)
Add to Google Calendar
Jun 23
Shareholder meeting 21:00
Shareholders' meeting
Venue: 東和薬品株式会社 本社2階会議室, 大阪府門真市新橋町2番11号 Details
Add to Google Calendar
May 14
Earnings 2:00
FY earnings announcement (scheduled)
Add to Google Calendar
Sep 27
Est.
Dividend Time TBD
Last day with rights (interim)
Add to Google Calendar
Sep 28
Est.
Ex-dividend Time TBD
Ex-rights date (interim)
Add to Google Calendar
Oct 29
Est.
Earnings 2:00 approx.
Q2 earnings
Add to Google Calendar
2027
Jan 21
Est.
Earnings 1:00 approx.
Q3 earnings
Add to Google Calendar
Mar 28
Est.
Dividend Time TBD
Last day with rights (year-end)
Add to Google Calendar
Mar 29
Est.
Ex-dividend Time TBD
Ex-rights date (year-end)
Add to Google Calendar
Apr 15
Est.
Earnings 2:00 approx.
Full-year earnings
Add to Google Calendar
Jul 8
Est.
Earnings 2:00 approx.
Q1 earnings
Add to Google Calendar

KPI highlights

FY26
Revenue ¥273.71B YoY +5.4%
Operating income ¥23.10B margin 8.4%
Net income ¥5.25B YoY -72.3%
EPS ¥107 YoY -72.3%
P/E —
ROE 3.0% Equity ratio 38% Typical equity ratios vary a lot by industry. Banks, brokerages, and other financial companies tend to run lower ratios because leverage (using other people's capital) is core to their business model — a low ratio there isn't a sign of financial weakness.

Company guidance

FY2027/03 Company-issued full-year guidance (from earnings report) / %=vs prior FY
Revenue ¥304.00B +11.1%
Operating income ¥32.00B +38.5%
Net income ¥21.50B +309.5%
EPS ¥431 +303.9%

Quarterly fundamentals

Income & cash flow
Quarter FY23 Q2FY23 Q3FY23 Q4FY24 Q1FY24 Q2FY25 Q2
Revenue ¥54.55B¥52.85B¥60.93B¥59.61B——
Operating income ¥4.10B¥2.91B¥6.20B¥4.44B——
Net income ¥4.75B¥2.20B¥4.57B¥4.66B——
Operating CF ——————

Ownership over time

Share of total shares outstanding (disclosed major holdings + undisclosed)（2021–2026）

事業法人 40.8%国内機関 14.1%海外機関 5.6%個人 8.1%未開示 30.1%202120222023202420252026
創業家事業法人国内機関海外機関個人未開示・浮動株

「国内機関」は信託銀行の名義口座（年金・パッシブ・一部海外資本を含む）を集計し、実質保有者へは分解していません。分類は開示名称からの推定です。

Top shareholders — rank & share

株式会社吉田事務所 40.8%株式会社吉田事務所日本マスタートラスト信託銀行株式会社 7.8%日本マスタートラスト信託銀行株式会社（信託口）US BANK NATIONAL A 4%US BANK NATIONAL ASSOCIATION JP ACCTS TS（常任代理人　株式会社三菱UFJ銀行）株式会社日本カストディ銀行（信託口） 3.3%株式会社日本カストディ銀行（信託口）東和薬品共栄会 3.1%東和薬品共栄会株式会社日本カストディ銀行（信託口4 3%株式会社日本カストディ銀行（信託口4）吉田　逸郎 3%吉田　逸郎東和薬品社員持株会 2%東和薬品社員持株会202120222023202420252026

Top shareholders — actual figures (as of 2026)

Holder Shares held Ratio Source
株式会社吉田事務所 20,100,000 40.8% Yuho (EDINET)
日本マスタートラスト信託銀行株式会社（信託口） 3,822,000 7.8% Yuho (EDINET)
US BANK NATIONAL ASSOCIATION JP ACCTS TS 1,961,000 4.0% Yuho (EDINET)
株式会社日本カストディ銀行（信託口） 1,638,000 3.3% Yuho (EDINET)
東和薬品共栄会 1,540,000 3.1% Yuho (EDINET)
株式会社日本カストディ銀行（信託口4） 1,459,000 3.0% Yuho (EDINET)
吉田 逸郎 1,455,000 3.0% Yuho (EDINET)
東和薬品社員持株会 1,000,000 2.0% Yuho (EDINET)
BNP PARIBAS LUXEMBOURG 2S JASDEC FIM LUXEMBOURG FUNDS UCITS ASSETS 800,000 1.6% Yuho (EDINET)
有限会社吉田エステート 648,000 1.3% Yuho (EDINET)

Source：EDINET（大株主の状況）　Classification inferred from disclosed names

F-Score (Piotroski)

6/9

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✓ Positive ROA ROA 1.1%
✓ Positive operating cash flow ¥30.43B
✗ ROA improved YoY 4.0% → 1.1%
✓ Operating CF exceeds net income (accrual quality) OCF ¥30.43B / net income ¥5.25B
✓ Equity ratio improved* Substitute for the original “decrease in long-term debt” 36.5% → 37.5%
✗ Current ratio improved 2.81× → 2.76×
✓ No dilution (shares outstanding did not increase) 51,516,000 → 51,516,000
✗ Gross margin improved 36.5% → 36.2%
✓ Asset turnover improved 0.55× → 0.58×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY26
Equity ratio 37.5%
Current ratio 2.8×
Years of positive operating CF 10 of last 10 yrs
Payout ratio 75%
Latest fiscal year result Profit (net income ¥5.25B)

Performance history

Last 10 years
0億円684億円1,369億円2,053億円2,737億円 FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

Income & assets

Unit: ¥100M
Item FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Revenue 8499341,0511,1041,5491,6562,0892,2792,5962,737
Operating income 68.711616016119919255.1176232231
Ordinary income 74.211718921018722751.4245262281
Net income 55.865.013514514015922.016219052.5
Total assets 1,6521,7731,8882,2812,4573,2993,7134,3074,7084,753
Equity 7497999181,0461,1661,3221,3691,5591,7161,781

Indicators & cash flow

*Split-adjustedUnit: ¥100M
Item FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
EPS ¥113¥132¥274¥295¥284¥323¥45¥329¥386¥107
ROE 7.7%8.4%15.7%14.8%12.6%12.8%1.6%11.0%11.6%3.0%
Operating CF 10219219019212022125.482.1234304
Investing CF -222-201-39.9-395-91.0-597-303-404-313-257
Financing CF -0.9246.7-8.091171.84465175354216-68.3
FCF -120-8.63150-20429.1-376-277-322-78.947.7

Source: EDINET (Annual Securities Report) (fetched 2026-08-29) *Some metrics supplemented from additional sources

Key financial metrics

3-year revenue growth ✓ Dividend grower ✓

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data